Arbutus Biopharma Corp Increase (Decrease) in Contract with Customer, Liability
Arbutus Biopharma Corp (ABUS) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2020-03-05
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for the quarter ending 2019-12-31 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for the quarter ending 2019-09-30 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for the quarter ending 2019-06-30 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for the quarter ending 2019-03-31 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for fiscal 2019 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for fiscal 2018 was -$2.74M, a 200.55% decline from fiscal 2017.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, liability for fiscal 2017 was $2.73M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | $0.00 10-K · filed 2020-03-05 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | -$649.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | -$649.00K derived: sum of 3 quarters · filed 2020-03-05 | -$974.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-06 | -$649.00K derived: sum of 2 quarters · filed 2020-03-05 | -$974.00K derived: sum of 3 quarters · filed 2020-03-05 | -$1.72M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-12-31 | -$649.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$974.00K derived: sum of 2 quarters · filed 2020-03-05 | -$1.72M derived: sum of 3 quarters · filed 2020-03-05 | -$2.74M 10-K · filed 2020-03-05 |
| 2018-09-30 | -$325.00K 10-Q · filed 2019-11-06 | -$1.07M derived: sum of 2 quarters · filed 2019-11-06 | -$2.09M 10-Q · filed 2019-11-06 | $634.00K derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | -$746.00K 10-Q · filed 2019-08-05 | -$1.77M 10-Q · filed 2019-08-05 | $959.00K derived: sum of 3 quarters · filed 2019-08-05 | -$5.78M derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | -$1.02M 10-Q · filed 2019-05-06 | $1.71M derived: sum of 2 quarters · filed 2019-05-06 | -$5.03M derived: sum of 3 quarters · filed 2019-05-06 | -$5.69M derived: sum of 4 quarters · filed 2019-05-06 |
| 2017-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$4.01M derived: sum of 2 quarters · filed 2019-03-07 | -$4.67M derived: sum of 3 quarters · filed 2019-03-07 | $2.73M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$6.74M 10-Q · filed 2018-11-07 | -$7.39M derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-06-30 | -$653.00K 10-Q · filed 2018-08-03 | $6.74M 10-Q · filed 2018-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |